
Alignment Healthcare, Inc.
HealthcareNASDAQ:ALHC · NASDAQ Global Select
-$0.49 today
Vol 4.31M · Avg 5.26M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$724.0K +99.4% | -$128.1M +13.6% | -$148.2M +1.0% | -$149.6M +23.4% | -$195.3M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $30.5M +12.6% | $27.1M +24.9% | $21.7M +23.9% | $17.5M +9.1% | $16.0M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $62.1M -12.7% | $71.1M +6.4% | $66.8M -18.2% | $81.7M -26.1% | $110.6M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $45.5M -25.3% | $60.9M +2905.5% | $2.0M +136.5% | -$5.6M +71.4% | -$19.4M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $0 +100.0% | -$34.3M -27.2% | -$26.9M +21.6% | -$34.4M -95.2% | -$17.6M | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $0 +100.0% | -$1.5M +77.0% | -$6.3M -146.2% | $13.7M +3044.9% | $437.0K | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $45.5M -52.9% | $96.6M +173.6% | $35.3M +134.2% | $15.1M +771.8% | -$2.2M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $2.6M -31.3% | $3.8M +343.4% | -$1.5M -114.6% | $10.6M +13.6% | $9.3M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $139.9M +302.4% | $34.8M +158.7% | -$59.2M -30.3% | -$45.4M +42.3% | -$78.8M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$26.8M +35.3% | -$41.4M -15.1% | -$36.0M -51.4% | -$23.8M -29.5% | -$18.4M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $1.1M | $0 | $0 +100.0% | -$4.0M | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$65.6M +20.2% | -$82.2M +78.3% | -$379.1M -13318.0% | -$2.8M -14.1% | -$2.5M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $76.3M -53.1% | $162.8M -39.2% | $267.8M +10942.9% | $2.4M +70.2% | $1.4M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 -100.0% | $14.0K | $0 | $0 +100.0% | -$1.4M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$15.0M -138.2% | $39.2M +126.6% | -$147.3M -421.9% | -$28.2M -35.6% | -$20.8M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 -100.0% | $165.0M | $0 -100.0% | $21.8M | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $18.1M | $0 | $0 | $0 -100.0% | $390.6M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 +100.0% | -$350.0K | $0 | $0 +100.0% | -$1.5M | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$26.0K +99.7% | -$8.6M -8311.4% | $105.0K +102.0% | -$5.2M +82.0% | -$29.0M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $18.0M -88.4% | $156.0M +148498.1% | $105.0K -99.4% | $16.6M -95.4% | $360.1M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $143.0M -37.8% | $230.0M +211.5% | -$206.3M -261.7% | -$57.1M -121.9% | $260.5M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $113.1M +1802.0% | -$6.6M +93.0% | -$95.2M -37.5% | -$69.2M +28.8% | -$97.1M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector

Oscar Health, Inc.
NYSE:OSCR
$7.33B

Apogee Therapeutics, Inc.
NASDAQ:APGE
$5.47B

Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
$4.99B

Envista Holdings Corp
NYSE:NVST
$4.00B

ICU Medical, Inc.
NASDAQ:ICUI
$3.55B

Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.01B

Privia Health Group, Inc.
NASDAQ:PRVA
$2.95B
Soleno Therapeutics, Inc.
SLNO
$2.76B

GRAIL, Inc.
NASDAQ:GRAL
$2.57B

Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.40B
SEC Filings
Recent regulatory filings
No filings found.
Does ALHC generate free cash flow?
Alignment Healthcare, Inc. (ALHC) generated $113.15M of free cash flow in fiscal 2025.
How much operating cash flow does ALHC produce?
Operating cash flow was $139.93M, before capital expenditures of $26.78M.
Explore More
Continue the stock analysis
Jump to another research area for this company.